It's no different from a biotech play although there is much more M&A activity in the agchem sector for promising compounds like ours which shortens the lifespan as investors.
Partnering will be the key and many global biotechs have market caps in the hundreds of millions with strategic partnerships in late stage trials. It will take many solutions to overcome the long term issue of insecticide resistance in all verticals.
The next step for Bio-gene is taking time for good reason, as
@Lefevre mentioned it's important to secure the right deal rather than any deal, especially after the Virbac withdrawal. Getting options in the money is a secondary target.
That being said it looks close, their website has been updated with greater detail and a new "Partners" section
View attachment 1372741The year as a whole has been incredibly productive for the company which has made real inroads in efficacy, toxicology and manufacturing from world class institutions including Purdue, CSIRO, Eurofins with the foundations built. Hence the opportunity.
